Abstract
Adenosine is produced primarily by the metabolism of ATP and mediates its physiological actions by interacting primarily with adenosine receptors (ARs) on the plasma membranes of different cell types in the body. Activation of these G protein-coupled receptors promotes activation of diverse cellular signaling pathways that define their tissuespecific functions. One of the major actions of adenosine is cytoprotection, mediated primarily via two ARs - A1 (A1AR) and A3 (A3AR). These ARs protect cells exposed to oxidative stress and are also regulated by oxidative stress. Stressmediated regulation of ARs involves two prominent transcription factors - activator protein-1 (AP-1) and nuclear factor (NF)-κB – that mediate the induction of genes important in cell survival. Mice that are genetically deficient in the p50 subunit of NF-κB (i.e., p50 knock-out mice) exhibit altered expression of A1AR and A2AAR and demonstrate distinct behavioral phenotypes under normal conditions or after drug challenges. These effects suggest an important role for NF-κB in dictating the level of expression of ARs in vivo, in regulating the cellular responses to stress, and in modifying behavior.
Keywords: dopaminergic neurons, Adenine nucleotides, mice,, caffeine, sleep, NF-κB, p50 knockout mice, adenosine receptor, Adenosine
Current Neuropharmacology
Title: Nuclear Factor κB and Adenosine Receptors: Biochemical and Behavioral Profiling
Volume: 9 Issue: 2
Author(s): Xiaobin Xie, Sarvesh Jajoo, Linda A. Toth, Krishna A. Jhaveri and Vickram Ramkumar
Affiliation:
Keywords: dopaminergic neurons, Adenine nucleotides, mice,, caffeine, sleep, NF-κB, p50 knockout mice, adenosine receptor, Adenosine
Abstract: Adenosine is produced primarily by the metabolism of ATP and mediates its physiological actions by interacting primarily with adenosine receptors (ARs) on the plasma membranes of different cell types in the body. Activation of these G protein-coupled receptors promotes activation of diverse cellular signaling pathways that define their tissuespecific functions. One of the major actions of adenosine is cytoprotection, mediated primarily via two ARs - A1 (A1AR) and A3 (A3AR). These ARs protect cells exposed to oxidative stress and are also regulated by oxidative stress. Stressmediated regulation of ARs involves two prominent transcription factors - activator protein-1 (AP-1) and nuclear factor (NF)-κB – that mediate the induction of genes important in cell survival. Mice that are genetically deficient in the p50 subunit of NF-κB (i.e., p50 knock-out mice) exhibit altered expression of A1AR and A2AAR and demonstrate distinct behavioral phenotypes under normal conditions or after drug challenges. These effects suggest an important role for NF-κB in dictating the level of expression of ARs in vivo, in regulating the cellular responses to stress, and in modifying behavior.
Export Options
About this article
Cite this article as:
Xie Xiaobin, Jajoo Sarvesh, A. Toth Linda, A. Jhaveri Krishna and Ramkumar Vickram, Nuclear Factor κB and Adenosine Receptors: Biochemical and Behavioral Profiling, Current Neuropharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157015911795596559
DOI https://dx.doi.org/10.2174/157015911795596559 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Tissue Plasminogen Activator (tPA) and Matrix Metalloproteinases in the Pathogenesis of Stroke: Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Cytochrome P450 in Neurological Disease
Current Drug Metabolism G Protein Coupled Receptors - In Silico Drug Discovery and Design
Current Topics in Medicinal Chemistry Heparins with Reduced Anti-Coagulant Activity Reduce Myocardial Reperfusion Injury
Recent Patents on Cardiovascular Drug Discovery Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry The Pathogenesis of Susceptibility to Acute Kidney Injury in the Elderly
Current Aging Science The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Activation and Control of CNS Innate Immune Responses in Health and Diseases: A Balancing Act Finely Tuned by Neuroimmune Regulators (NIReg)
CNS & Neurological Disorders - Drug Targets Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Biological and Pharmacological Activities of Carvacrol and Carvacrol Bearing Essential Oils
Current Pharmaceutical Design Complications Following Stem Cell Therapy in Inflammatory Bowel Disease
Current Stem Cell Research & Therapy Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?
Current Diabetes Reviews Design of Iodine-Lithium-α-Dextrin Liquid Crystal with Potent Antimicrobial and Anti-Inflammatory Properties
Current Pharmaceutical Design The Role of Mitochondria in Piperine Mediated Cardioprotection in Isoproterenol Induced Myocardial Ischemia
Current Pharmaceutical Design Structure, Function and Control of Complement C5 and its Proteolytic Fragments
Current Molecular Medicine Measurement of the Endogenous Adenosine Concentration in Humans In Vivo: Methodological Considerations
Current Drug Metabolism The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Targeting the Inflammatory Response in Healing Myocardial Infarcts
Current Medicinal Chemistry Cell-Selective Mitochondrial Targeting: Progress in Mitochondrial Medicine
Current Drug Delivery A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update
Current Medicinal Chemistry